Klotho Specific Neutra™ Antibody Products

Are you struggling with prolonged therapeutic development timelines or inconsistent functional validation of anti-aging targets? Creative Biolabs' Klotho specific Neutra™ antibody products overcome these barriers by leveraging advanced epitope-specific engineering and high-throughput validation platforms, enabling precise neutralization of Klotho to accelerate your research on aging-associated pathologies.

Introduction to Klotho

Klotho, an evolutionary conserved protein first identified in 1997, functions as a multifunctional regulator of aging, metabolism, and oxidative stress. It exists in membrane-bound and soluble forms, with the latter acting as a circulating hormone modulating systemic phosphate homeostasis and insulin sensitivity. Klotho deficiency correlates directly with accelerated aging phenotypes and age-related disorders.

Structural Insights

The membrane-bound Klotho protein comprises two extracellular β-glucosidase-like domains connected by a transmembrane anchor. Its soluble form arises from alternative splicing or ectodomain shedding. Structural studies reveal that the C-terminal domain mediates interactions with fibroblast growth factor receptors (FGFRs), while the N-terminal domain binds phosphate-regulating hormones. Cryo-EM analyses demonstrate conformational flexibility in its FGF23-binding interface, a critical feature for therapeutic antibody targeting.

Signaling Pathways

Klotho modulates three key pathways:

• FGF23-Klotho-FGFR Axis: Essential for phosphate and vitamin D metabolism. Klotho acts as a co-receptor for FGF23, enhancing FGFR1c affinity and downstream signaling to regulate renal phosphate excretion.
• Wnt/β-Catenin Pathway: Soluble Klotho inhibits Wnt signaling, protecting tissues from fibrosis and calcification.
• Insulin/IGF-1 Signaling: Klotho suppresses insulin/IGF-1 receptor activation, improving cellular stress resistance and longevity.

Fig.1 Various pathways of Klotho.¹

Disease Relevance

Klotho deficiency drives chronic kidney disease progression, vascular calcification, osteoporosis, and neurodegenerative disorders. Its soluble form is markedly reduced in patients with renal failure, cardiovascular disease, and Alzheimer's, positioning Klotho restoration as a therapeutic priority.

Fig.2 Klotho deficiency associates with multiple age-related diseases.¹

Therapeutic Applications of Klotho Neutralizing Antibodies

• Reversing Age-Related Organ Dysfunction

Anti-Klotho antibodies restore phosphate homeostasis in chronic kidney disease by blocking FGF23-Klotho-FGFR hyperactivation, reducing renal fibrosis and secondary hyperparathyroidism in preclinical models.

• Combatting Metabolic Syndrome

Neutralizing antibodies targeting soluble Klotho improve insulin sensitivity and glucose uptake in adipose tissue, offering potential for diabetes management.

• Oncology Interventions

In cancers with aberrant Klotho overexpression (e.g., breast and pancreatic carcinomas), antibodies inhibit pro-survival signaling, sensitizing tumors to chemotherapy.

• Neuroprotection

Antibodies that stabilize soluble Klotho levels show promise in mitigating tau hyperphosphorylation and synaptic loss in Alzheimer's models.

Anti-Klotho Antibodies

Creative Biolabs' anti-Klotho neutralizing antibodies target functional epitopes to either block pathological Klotho interactions or enhance its protective signaling. Key features include:

• High Specificity: Antibodies selectively bind the FGF23-binding domain, disrupting pathogenic FGFR activation in renal and vascular tissues.
• Dual-Activity Formats: Engineered variants simultaneously neutralize excess soluble Klotho in hyperphosphatemia while preserving membrane-bound Klotho's anti-apoptotic effects.
• Preclinical Validation: Demonstrated efficacy in reversing vascular calcification in uremic models and improving cognitive function in neurodegeneration assays.

Creative Biolabs delivers rigorously validated Klotho specific antibodies tailored for translational research and therapeutic development. Our solutions combine structural precision with functional versatility to address complex age-related pathologies.

Contact our scientific team today to explore customized antibody strategies for your Klotho-focused projects.

REFERENCE

1. Prud'homme, Gérald J., Mervé Kurt, and Qinghua Wang. "Pathobiology of the klotho antiaging protein and therapeutic considerations." Frontiers in Aging 3 (2022): 931331. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fragi.2022.931331